yahoo_financeOriginal article
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
Data ReadoutpositiveSefaxersenPositive
AI Analysis
Summary
Genentech announced positive interim data demonstrating that sefaxersen significantly reduces proteinuria in patients with IgA Nephropathy. The positive efficacy signal supports continued clinical development of the candidate.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Sefaxersen significantly reduces proteinuria in people with IgA Nephropathy
Importance:7/10
Sentiment:
0.80
Phase 2Interim DataNephrologyProteinuria Reduction
Related Companies
Read the original article
Published by yahoo_finance on September 23, 2026 5:00 AM